The Impact of genistein on oxidative stress biomarkers in erythrocytes: A study in IPD patients

Abstract

The pathophysiology of Idiopathic Parkinson’s disease (IPD), a progressive neurodegenerative condition, is extensively affected by oxidative stress. IPD is a multifactorial disease in which oxidative stress damage the systemic cellular system, along with the central nervous system. However, the peripheral biomarkers imbalance and therapeutic responses in IPD remain restricted. In this study, erythrocytes from healthy control and IPD patients were used to evaluate the impact of Genistein on oxidative stress biomarkers. The assessment was conducted on medically appropriate blood samples collected from 95 subjects out of which (n=45) are healthy control and (n=50) are IPD patients. The impact of genistein were assessed against oxidative stress induced by 10mM H₂O₂, evaluated by quantifying the levels of MDA, GSH, SOD and Catalase after co-incubation of erythrocytes with genistein (10^-7M to 10^-5M) and H₂O₂. The outcomes showed elevated MDA levels and SOD activity (P<0.001) and decreased catalase activity and GSH levels (P<0.001) after incubation with H₂O₂. Genistein, when administered in vitro, effectively mitigated oxidative stress-induced damage in red blood cells from all individuals. These findings, validate the present study by providing genistein’s systemic antioxidant effectiveness and reinforcing the significance of erythrocyte-based oxidative indicators in IPD. This study helps to fulfil the gap of growing demand for reliable, non-invasive biomarkers to evaluate the oxidative stress in IPD.